Objectives: To evaluate the effect and safety of Infliximab (Remicade) for 14 - week treatment of Ankylosing Spondylitis (AS). Subjects and Methods: This prospective, descriptive, cross sectional study was carried out on 60 in patients diagnosed with AS according to ACR - 1984 criteria at Bach mai Hospital and E Hospital. The patients were divided into two groups, Including group 1: 30 consecutive patients treated with Sufasalazine and Non - steroidal anti inflammatory drugs (NSAIDs), and group 2: 30 others treated with Infliximab and NSAIDs during 14 weeks. Results. After 14 - week duration of study, group 2 had significant improvement in noctunal back pain, BASDAI, BASA, spinal mobility, reduction of dose of NSAIDs used concomitantly, CRP level and erythrocyte sedimentation rate. Infliximab treatment were generally well tolerated, there were no dlscontlmuations for safety reasons. Conclusion. Inflixlmab is effective and safe for treatment of Vietnamese patient with Ankylosing Spondylitis.